<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The distinction between Burkitt (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) or atypical Burkitt/Burkitt-like <z:hpo ids='HP_0002665'>lymphomas</z:hpo> harboring a MYC translocation (MYC+) and diffuse large B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCLs</z:e>) with high proliferation fractions but without a MYC translocation (MYC-) can be difficult using standard morphologic and immunohistochemical criteria </plain></SENT>
<SENT sid="1" pm="."><plain>Recently, unique gene expression profiles differentiating <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> were reported and include higher transcript levels of T-cell <z:hpo ids='HP_0001909'>leukemia</z:hpo>-1 (TCL1) and CD38 and lower transcript levels of CD44 in MYC+ <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> relative to MYC- <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>We examined a cohort of 67 cytogenetically defined aggressive <z:hpo ids='HP_0002665'>lymphomas</z:hpo> using immunohistochemical techniques for expression of TCL1, CD38, and CD44 and found distinct expression patterns between MYC+ and MYC- <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Furthermore, these markers are better predictors of MYC status than combined staining for CD10 and BCL2 </plain></SENT>
<SENT sid="4" pm="."><plain>Thus staining for TCL1, CD38, and CD44 are useful ancillary tests to identify B-cell <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> for which confirmatory cytogenetic and/or fluorescent in situ hybridization studies assessing the status of the MYC locus should be pursued </plain></SENT>
</text></document>